4,050 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Searle & CO.

Searle & CO. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,050 shares of the biopharmaceutical company’s stock, valued at approximately $328,000.

Other hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $26,000. Tompkins Financial Corp lifted its holdings in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Rakuten Securities Inc. acquired a new position in Gilead Sciences in the 4th quarter worth approximately $33,000. Finally, Financial Connections Group Inc. acquired a new stake in Gilead Sciences during the 4th quarter valued at $40,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Cantor Fitzgerald dropped their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Oppenheimer reissued an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. TD Cowen cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Finally, Maxim Group cut their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $83.69.

Gilead Sciences Price Performance

Shares of GILD traded up $0.31 during mid-day trading on Wednesday, reaching $65.51. The company had a trading volume of 7,072,300 shares, compared to its average volume of 7,476,059. The company’s 50-day moving average is $71.03 and its 200-day moving average is $76.08. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The company has a market capitalization of $81.57 billion, a P/E ratio of 180.53, a P/E/G ratio of 1.30 and a beta of 0.19. Gilead Sciences, Inc. has a twelve month low of $64.63 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter last year, the company posted $1.37 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 3.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.70%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is presently 855.56%.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.